Skip to main content
. Author manuscript; available in PMC: 2023 Dec 5.
Published in final edited form as: Mol Pharm. 2022 Jul 25;19(12):4393–4410. doi: 10.1021/acs.molpharmaceut.2c00222

Figure 7.

Figure 7.

Overview of (a) formation of hybrid nanofilaments as a delivery system for the treatment of colitis. (b) Treatment regimens and efficacy for different experimental groups: normal control (NC), DSS-induced mouse control (DSS), amyloid-EGCG hydrogel treatment (DH), EGCG treatment (DE), and amyloid fibrils treatment (DF). All were given 2 wt % DSS except for NC, which was given purified water. Different letters between data groups indicate statistically significant differences. Reprinted with permission from Hu et al.54 Copyright 2020 American Chemical Society.